{
    "id": "2af04cce-d969-4899-8040-970c6503700f",
    "indications": {
        "text": "divalproex sodium delayed-release capsule anti-epileptic indicated : monotherapy adjunctive therapy complex partial seizures simple complex absence seizures ; adjunctive therapy patients multiple seizure types include absence seizures ( 1 )",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "\u2022 divalproex sodium delayed-release capsules may swallowed whole contents may sprinkled soft food . drug/food mixture swallowed immediately ( avoid chewing ) ( 2.2 ) \u2022 safety doses 60 mg/kg/day established ( 2.1 , 2.2 ) \u2022 complex partial seizures : start 10 15 mg/kg/day , increasing 1 week intervals 5 10 mg/kg/day achieve optimal response ; response satisfactory , check valproate plasma level ; full prescribing information conversion monotherapy ( 2.1 ) \u2022 absence seizures : start 15 mg/kg/day , increasing 1 week intervals 5 10 mg/kg/day seizure control limiting side effects ( 2.1 )",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "divalproex sodium delayed-release capsules usp , 125 mg oral white off-white , coated particles filled \u2018 size 1 \u2019 hard gelatin capsules light blue transparent cap imprinted \u2018 \u2011 \u2191this end up\u2191 \u2011 \u2019 white opaque body imprinted \u2018 rdy 532 \u2019 body using black ink supplied overbagged 10 delayed-release capsules per bag , ndc 55154-3552-0 recommended storage : store 20\u00b0-25\u00b0c ( 68\u00b0-77\u00b0f ) ; [ usp controlled room temperature ] .",
    "adverseReactions": "\u2022divalproex sodium delayed-release capsules administered patients hepatic disease significant hepatic dysfunction [ ( 5.1 ) ] . \u2022divalproex sodium delayed-release capsules contraindicated patients known mitochondrial disorders caused mutations mitochondrial dna polymerase \u03b3 ( polg ; e.g . , alpers-huttenlocher syndrome ) children two years age suspected polg-related disorder [ ( 5.1 ) ] . \u2022divalproex sodium delayed-release capsules contraindicated patients known hypersensitivity [ ( 5.12 ) ] . \u2022divalproex sodium delayed-release capsules contraindicated patients known urea cycle disorders [ ( 5.6 ) ] . \u2022for prophylaxis migraine headaches : divalproex sodium delayed-release capsules contraindicated women pregnant women childbearing potential using effective contraception [ ( 5.2 , 5.3 , 5.4 ) ( 8.1 ) ] .",
    "ingredients": [
        {
            "name": "DIVALPROEX SODIUM",
            "code": "644VL95AO6"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50821"
        },
        {
            "name": "D&C RED NO. 28",
            "code": "767IP0Y5NH"
        },
        {
            "name": "ETHYLCELLULOSE, UNSPECIFIED",
            "code": "7Z8S9VYZ4B"
        },
        {
            "name": "FD&C BLUE NO. 1",
            "code": "H3R47K3TBD"
        },
        {
            "name": "GELATIN, UNSPECIFIED",
            "code": "2G86QN327L",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_5291"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "RAW SUGAR",
            "code": "8M707QY5GH"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "TRIETHYL CITRATE",
            "code": "8Z96QXD6UM",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_168426"
        }
    ],
    "organization": "Cardinal Health 107, LLC",
    "name": "Divalproex sodium",
    "effectiveTime": "20250421",
    "indications_original": "Divalproex sodium delayed-release capsule is an anti-epileptic drug indicated for : Monotherapy and adjunctive therapy of complex partial seizures and simple and complex absence seizures; adjunctive therapy in patients with multiple seizure types that include absence seizures (1)",
    "contraindications_original": "\u2022 Divalproex sodium delayed-release capsules may be swallowed whole or the contents may be sprinkled on soft food. The drug/food mixture should be swallowed immediately (avoid chewing) ( 2.2 ) \u2022 Safety of doses above 60 mg/kg/day is not established ( 2.1 , 2.2 ) \u2022 Complex Partial Seizures: Start at 10 to 15 mg/kg/day, increasing at 1 week intervals by 5 to 10 mg/kg/day to achieve optimal clinical response; if response is not satisfactory, check valproate plasma level; see full prescribing information for conversion to monotherapy ( 2.1 ) \u2022 Absence Seizures: Start at 15 mg/kg/day, increasing at 1 week intervals by 5 to 10 mg/kg/day until seizure control or limiting side effects (2.1)",
    "warningsAndPrecautions_original": "Divalproex sodium delayed-release capsules USP, 125 mg\u00a0 for oral use are white to off-white, coated particles filled in \u2018size 1\u2019 hard gelatin capsules of light blue transparent cap imprinted\u00a0\u2018\u2011 \u2191THIS END UP\u2191 \u2011\u2019 and white opaque body imprinted \u2018RDY 532\u2019 on the body using black ink and are supplied \n                  Overbagged with 10 delayed-release capsules per bag, NDC 55154-3552-0\n                  Recommended Storage : Store at 20\u00b0-25\u00b0C (68\u00b0-77\u00b0F); [See USP Controlled Room Temperature].",
    "adverseReactions_original": "\u2022Divalproex sodium delayed-release capsules should not be administered to patients with hepatic disease or significant hepatic dysfunction [see \n                           Warnings and Precautions (5.1)\n                        ].\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \n                     \n                        \u2022Divalproex sodium delayed-release capsules are contraindicated in patients known to have mitochondrial disorders caused by mutations in mitochondrial DNA polymerase \u03b3 (POLG; e.g., Alpers-Huttenlocher Syndrome) and children under two years of age who are suspected of having a POLG-related disorder [see Warnings and Precautions (5.1)]. \n                     \n                        \u2022Divalproex sodium delayed-release capsules are contraindicated in patients with known hypersensitivity to the drug [see Warnings and Precautions (5.12)].\n                     \n                        \u2022Divalproex sodium delayed-release capsules are contraindicated in patients with known urea cycle disorders [see Warnings and Precautions (5.6\n                        )].\n                     \n                        \u2022For use in prophylaxis of migraine headaches: Divalproex sodium delayed-release capsules are contraindicated in women who are pregnant and in women of childbearing potential who are not using effective contraception [see Warnings and Precautions (5.2,\u00a05.3,\u00a05.4) and Use in Specific Populations (8.1)].",
    "drug": [
        {
            "name": "Divalproex sodium"
        }
    ]
}